论文部分内容阅读
Specific antibodies or antibody-fusion proteins are produced now in kg to ton quantities for the treatment of a small number of diseases, benefiting tens of thousands of affected patients.The unprecedented medical and commercial success of these molecules has raised enormous interest in the biopharmaceutical research community, resulting in hundreds of new molecules to be explored for the same or other diseases.